CD274 and neoplasm: We highlight emerging biomarker strategies that integrate spatial transcriptomics to map immune exclusion zones, along with liquid biopsy monitoring of exosomal PD-L1 and circulating tumor DNA, to enable real-time adaptation of combination immunotherapy regimens.